From his early days as an interior contractor to pioneering architectural finishes for high-containment environments, Ghislain’s story is one of vision and grit. What began with a simple request from IBM for a low-maintenance wall system evolved into a revolutionary idea—transforming industrial-grade polymers into architectural solutions.

That spark led to the birth of Arcoplast.

Despite early skepticism and industry challenges, Ghislain saw potential where others didn’t. He focused on sectors where performance mattered most—dairy, food production, and high-containment environments—and built a company that didn’t just meet expectations but redefined them.

“I’m proud that we’ve built something truly unique; products others don’t dare attempt,” Ghislain shared. “We shine because we’re so far ahead of the curve.” The acquisition by Germfree in 2024 was a milestone that validated Arcoplast’s mission and values. “It wasn’t just any acquisition. It was by a client that I deeply respect. We made each other better over many years,” he reflected. As he steps away, Ghislain leaves Arcoplast in the capable hands of Steve Sebastian, a leader he describes as humble, brilliant, and deeply respected. “What took me a lifetime to learn, he’s mastered in five years,” Ghislain said. “I couldn’t ask for a better person to lead the next chapter.”

“Ghislain’s impact on Arcoplast and the industry is immeasurable. His ability to see opportunity where others saw limitation has shaped not only Arcoplast but also Germfree and the standards of our field. I’m honored to carry forward his legacy and excited to work alongside the next generation of talent at both Germfree and Arcoplast. The future is bright, the combination of our teams is unstoppable, and we’re just getting started. Please join us in celebrating Ghislain’s extraordinary career and the exciting road ahead for Arcoplast!” stated Kevin Kyle, CEO of Germfree.

To our customers, partners, and team: Arcoplast’s mission remains unchanged. The foundation is strong, the leadership is solid, and the future is bright. Ghislain’s legacy will continue to inspire us as we build on his vision—creating environments that stand the test of time.

Boston, MA, June 17, 2025 – At the BIO International Convention 2025 in Boston, King Faisal Specialist Hospital & Research Centre (KFSHRC) and Germfree Laboratories, LLC announced a strategic partnership to develop Saudi Arabia’s first fully integrated, modular Advanced Therapy Medicinal Product (ATMP) Manufacturing Campus.

The new facility will be located at KFSHRC’s main campus in Riyadh and will serve as a critical milestone in advancing Vision 2030 and the National Biotechnology Strategy, two national initiatives aimed at transforming the Kingdom into a global hub for life sciences, biomanufacturing, and to become a global biotech hub by 2040.

“This initiative marks a historic milestone, not just for our institution, but for the Kingdom of Saudi Arabia in alignment with Vision 2030 and the National Biotechnology Strategy,” said His Excellency Dr. Majid bin Ibrahim Al Fayyadh, CEO of KFSHRC. “With Germfree as our partner, we are creating a world-class advanced therapies campus that will accelerate access to transformative treatments, draw the brightest minds in science, and strengthen Saudi Arabia’s position as a global leader in biotechnology. This fast-track, strategic project represents a continuation of the long history of healthcare innovation that has been realized by King Faisal Specialist Hospital and Research Centre.”

“KFSHRC’s leadership and vision align with Germfree’s mission to expand access to complex therapies through future-proofed, agile infrastructure,” said Kevin Kyle, CEO of Germfree Laboratories. “Together, we are building much more than a facility for Cell & Gene Therapy manufacturing, we’re building a turnkey, scalable platform for discovery and delivery of curative therapies for the people of Saudi Arabia, the Middle East, and beyond. This collaboration reflects the critical role infrastructure plays in unlocking access to advanced therapies, and we are proud to support KFSHRC’s vision for patient-centric care.”

Under the terms of a signed Letter of Intent, the turnkey project will fast-track the Kingdom’s ability to manufacture cell and gene therapies locally, host international clinical trials, and attract leading pharmaceutical partnerships and scientific talent from around the world.

This project directly supports Saudi Arabia’s National Biotechnology Strategy, launched to localize vaccine and therapeutic production, develop sovereign biomanufacturing capabilities, and establish the Kingdom as a global biotechnology leader by 2040.

As a core pillar of Vision 2030, the strategy aims to make Saudi Arabia a destination for clinical trials, scientific discovery, pharmaceutical investment, and biotech entrepreneurship across the Middle East and beyond.

By establishing a globally competitive manufacturing campus, KFSHRC is not only advancing national healthcare; it is setting a new global standard for innovation, scalability, and patient-centered care.

King Faisal Specialist Hospital & Research Centre is Saudi Arabia’s foremost tertiary-and-quaternary referral institution, delivering world-class care in oncology, transplantation, cardiovascular medicine and precision therapeutics. It is ranked No. 1 in the Middle East & Africa and 15th globally among academic medical centers by Brand Finance’s 2025 report and is listed on Newsweek’s World’s Best Hospitals as well as World’s Best Smart Hospitals 2025. As a flagship partner in the Kingdom’s Vision 2030 and National Biotechnology Strategy an initiative to localize biomanufacturing and make Saudi Arabia a global biotech hub by 2040, KFSHRC forges international collaborations, drives cutting-edge clinical research, and cultivates Saudi scientific talent to expand patient access to life-changing therapies.

Ormond Beach, FL, Nov. 12, 2024 – Germfree Laboratories, On Demand Pharmaceuticals (ODP), and North Mississippi Medical Center-Tupelo (NMMC) have teamed up to address the global drug shortage crisis with a groundbreaking point-of-care medicine production solution. The expanding partnership aims to bring agile production of essential medicines closer to the point of care across the country and globally, ensuring a reliable supply of life-saving drugs.

With more than 75% of U.S. hospitals facing medication shortages and millions of people in low- and middle-income countries lacking access to critical medicines, the need for localized, flexible production is urgent. By combining Germfree’s mobile cleanroom technology with ODP’s Pharmacy on Demand platform, this collaboration empowers healthcare providers to produce high-quality medications on site, reducing reliance on fragile global supply chains.

The partnership builds on a six-month pilot study that leveraged ODP’s platform technology and Germfree’s mobile cleanroom capability to produce syringes of common shortage medicines at NMMC, including lidocaine, rocuronium, and potassium chloride. This real-world pilot met all regulatory requirements, leveraged a state-of-the art quality management approach, and demonstrated a novel, agile compounding capability for drugs on shortage. It resulted in patients being treated with high-quality medicines that were made on-demand and on-site.

“We’re not just filling gaps in the supply chain, we’re redefining it,” said Kevin Kyle, CEO of Germfree. “With On Demand Pharma, we are enabling healthcare providers to meet patient needs faster and more reliably, whether in urban centers or rural areas. This partnership also demonstrates our commitment to using cutting-edge technologies to improve the way hospital pharmacies respond to the needs of their patients, with more to come.”

Matt Pietras, CEO of On Demand Pharmaceuticals, added, “This collaboration with Germfree provides us with the high-quality modular infrastructure needed to provide our Medication-as-a-Service (MaaS) where patients and healthcare providers need it most.”

The innovative model will allow hospitals like NMMC to produce critical medications locally, improving access for patients and ensuring continuity of care even during global supply disruptions. “Our pilot work completed through this collaboration has proven these new capabilities for on-site compounded medications are able to help us better serve our communities in a timelier manner,” said Wes Pitts, System Director of Pharmacy at North Mississippi Health Services, which includes NMMC in Tupelo. “In our pilot program, we were able to successfully compound approximately 12,000 doses of shortage medications starting in December 2023 following regulations from the Board of Pharmacy.”

“We are on the cusp of expanding distributed medicine production through our network while creating a new paradigm,” said John Lewin, Chief Medical Officer at ODP. “I envision a future where pharmacists take a leading role in medicine production – both today and as personalized medicine becomes the standard at the point of care.”

The collaboration between Germfree and On Demand Pharmaceuticals is set to transform the future of medicine accessibility by providing healthcare providers with the tools to produce medications on demand, whenever and wherever they are needed.

About Germfree Laboratories: Germfree Laboratories is a global leader in cleanroom and critical environment technologies, specializing in providing innovative solutions for biopharmaceutical, healthcare, and research sectors. Learn more at www.germfree.com.

About On Demand Pharmaceuticals: On Demand Pharmaceuticals (ODP) is revolutionizing pharmaceutical access with its Pharmacy on Demand platform, offering agile, on-site production of medications. ODP is committed to overcoming industry barriers and ensuring high-quality medicines are accessible to all. Learn more at www.ondemandpharma.com.

About North Mississippi Medical Center: North Mississippi Medical Center (NMMC) is one of the largest non-metropolitan hospitals in the U.S., providing comprehensive medical services to a growing community. NMMC is committed to innovation in healthcare delivery to ensure high-quality, accessible care for its patients. For more information, visit www.nmhs.net.

SOURCE Germfree Laboratories LLC

Media Contacts:
Germfree Laboratories:
Lauren Blum, Content Marketing Manager
marketing@germfree.com

On Demand Pharmaceuticals:
Media Relations
media@ondemandpharma.com

North Mississippi Medical Center:
Deborah Pugh
drpugh@nmhs.net

ORMOND BEACH, Fla., Oct. 14, 2024 /PRNewswire/ — Germfree, a pioneering leader in modular and mobile cleanroom infrastructure, equipment and services, today announced the acquisition of Arcoplast, maker of the leading seamless primary barrier cleanroom wall and ceiling system for Life Science applications and more. The acquisition will allow Germfree to offer comprehensive facility solutions from the ground up and follows 17 years of collaboration between the companies, during which Arcoplast has supplied architectural systems for Germfree installations at over 200 facilities globally.

Arcoplast primary barrier systems form the basis of design for BSL-3, ABSL-3, BSL-4, high-tech laboratories, and cleanrooms from NIH to CDC to NASA, throughout academia and in industries ranging from cell and gene therapy to food and beverage. Architects, engineers, and lab planners depend on the safety, durability, and long life cycle of Arcoplast’s wall and ceiling systems. The Arcoplast system is differentiated from others through their numerous certifications around environmental sustainability while also being by far the most durable architectural finish available to Life Science clients, eliminating the need for maintenance. As well, the non-porous, ultra-smooth surface finishes, seamless panels, and high-performance Bio-Seal systems combine to enable best-in-class cleaning, disinfecting, and bio-decontamination that is backed up by science and testing.

“Coming together with Arcoplast is critical for the next phase of Germfree’s growth, as we expand beyond mobile and modular spaces to fixed-facility and hybrid, turnkey facility solutions. I welcome the Arcoplast team to the Germfree family,” said Kevin Kyle, CEO of Germfree. “We’ve known and worked with these incredible people for many years and will now further leverage our combined experience to offer stick-built construction of cleanrooms, biocontainment facilities and more with Arcoplast’s unique interior finishes that are the most durable, most sustainable, and most tested system available. The combination of Germfree’s facility and equipment expertise with Arcoplast’s architectural finishes is one way that we will continue to unlock the scientific potential of our global client base.”

“As one of the largest users of our architectural systems, Germfree has long understood the importance of using the highest-quality materials for its builds in support of its projects across both the developed and undeveloped world,” said Ghislain Beauregard, President of Arcoplast. “Our company cultures are perfectly aligned around client service and innovation. This acquisition reflects a shared commitment to our pursuit of greener and more robust laboratories, hospital pharmacies, and cGMP facilities thanks to years of R&D and testing that have gone into Arcoplast composite materials. Together, we look forward to showing the market a better solution with improved constructability and lower environmental impact, with no rejuvenating maintenance program requirements for the facilities of the future.”

A seamless, end-to-end service that includes both infrastructure and highly specialized containment systems is key to streamlining construction processes and reducing project timelines.

To see the revolutionary Arcoplast system in person, visit Germfree’s booth #1529 this week at the 2024 International Society for Pharmaceutical Engineering (ISPE) Annual Meeting & Expo in Orlando, Florida.

About Germfree
Germfree Laboratories has become a globally recognized authority in cutting-edge critical environment equipment, cleanrooms, and laboratories for over six decades. The company has consistently led the way in pioneering cleanroom design and manufacturing, serving the biopharmaceutical, healthcare, and research sectors. Germfree remains resolutely committed to providing innovative solutions that significantly improve patient access to life-changing therapies. Germfree is backed by the healthcare growth equity investor, EW Healthcare Partners.  Learn more about partnering with Germfree at www.germfree.com.

About Arcoplast
Arcoplast has an international reputation as an industry leader in the field of high containment and controlled environments. Arcoplast earned its reputation by meeting compliancy standards all around the world, passing numerous laboratory tests, and enduring over 30 years real time scientific and industrial workloads.

SOURCE Germfree Laboratories LLC

Germfree Contact:
Lauren Blum, Content Marketing Manager
marketing@germfree.com

Media Contacts:
IB Communications
Tel +44 (0)20 89434685
germfree@ibcomms.agency